Kiadis Pharma announces Annual Results for the year end­ed 31 December 2015

Amsterdam, The Netherlands, April 15, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces its audit­ed annu­al results for the year end­ed 31 December 2015, which have been pre­pared in accor­dance with International Financial Reporting Standards (IFRS) as adopt­ed by the European Union.

Operating high­lights (includ­ing post the peri­od end)

– Strong progress was made in devel­op­ing lead prod­uct ATIR101™ for blood can­cer:
– full enrol­ment of the sin­gle dose Phase II clin­i­cal tri­al was com­plet­ed;
– pos­i­tive data was pre­sent­ed at the American Society of Hematology (ASH) Annual Meeting in December 2015;
– pos­i­tive results on the pri­ma­ry end­point were pre­sent­ed at the Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT) in April 2016;
– a fur­ther repeat-dos­ing Phase II clin­i­cal tri­al with ATIR101™ com­menced patient enrol­ment in October 2015;
– a closed man­u­fac­tur­ing process for ATIR101™ was estab­lished which allows for automa­tion;
– prepa­ra­tions to ini­ti­ate a ran­domised Phase III tri­al with ATIR101™ in the sec­ond half of 2016 are under­way;
– ATIR101™ was grant­ed an Advanced Therapy Medicinal Product (ATMP) cer­tifi­cate for man­u­fac­tur­ing qual­i­ty and non-clin­i­cal data by the European Medicinal Agency (EMA).
– Entered into a part­ner­ship with the U.S. Leukemia & Lymphoma Society, the world’s largest vol­un­tary health agency ded­i­cat­ed to blood can­cer in ear­ly 2016.
– Signed a col­lab­o­ra­tion with the Thalassaemia International Federation (TIF), an inter­na­tion­al­ly renowned organ­i­sa­tion that seeks to address the needs of patients, car­ers, health­care pro­fes­sion­als and the gen­er­al pub­lic in the area of tha­las­saemia for ATIR201™ in inher­it­ed blood dis­or­ders.

Financial high­lights
– Shares list­ed via an ini­tial pub­lic offer­ing (IPO) on Euronext Amsterdam and Euronext Brussels on 2 July 2015 rais­ing gross pro­ceeds of EUR34.7 mil­lion.
– The equi­ty posi­tion of the Company improved sig­nif­i­cant­ly and increased to EUR25.7 mil­lion at year-end 2015 com­pared to EUR2.7 mil­lion at the end of 2014.
– With net pro­ceeds of EUR31.2 mil­lion raised in the IPO, the Company’s cash posi­tion improved to EUR28.7 mil­lion at year-end 2015, which is an increase of EUR23 mil­lion com­pared to cash of EUR5.7 mil­lion at the end of 2014.
– Operating loss increased to EUR16 mil­lion in 2015 from a loss of EUR6.2 mil­lion in 2014.
– Operating expens­es for 2015 includ­ed non-cash share-based pay­ments of EUR7.8 mil­lion.
– Net loss increased from EUR7.8 mil­lion in 2014 to EUR16.5 mil­lion in 2015.

A full annu­al report for the year end­ed 31 December 2015 is avail­able in the For Investors sec­tion of this web­site.

Commenting on the annu­al results, Manfred Rüdiger, CEO of Kiadis Pharma, said: “2015 has been a very suc­cess­ful year for Kiadis Pharma. We reached sig­nif­i­cant mile­stones in our clin­i­cal pro­grammes and also suc­cess­ful­ly list­ed the Company on Euronext Amsterdam and Euronext Brussels. The finan­cial results are ful­ly in line with our guid­ance and pro­jec­tions and show that Kiadis Pharma has been con­scious and dili­gent on expens­es whilst pro­gress­ing with the devel­op­ment of its lead prod­uct ATIR101™ for patients suf­fer­ing from acute leukaemia towards its last phase of clin­i­cal devel­op­ment. With a healthy year-end cash posi­tion, we are well posi­tioned to begin Phase I/II clin­i­cal devel­op­ment with ATIR201™ for tha­las­saemia, scale-up our man­u­fac­tur­ing and begin enrol­ment into our piv­otal Phase III tri­al with ATIR101™. I would like to thank our investors for their con­tin­ued sup­port and look for­ward to pro­vid­ing fur­ther updates in due course.

Leave a Reply

Your email address will not be published. Required fields are marked *